Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...

Global M&A activity jumped nearly 50% in 2025, reaching $4.5 trillion, based on data from the London Stock Exchange Group. It’s the highest annual total since 2021, when the pandemic frenzy pushed ...

Deal-makers across industries in the U.S. anticipated the floodgates to open in 2025 with the expectation of looser regulations with President Donald Trump in office. M&A activity didn't live up to ...

If your corporation is focused on delivering a high return on capital for its shareholders, you should consider M&A as an integral part of your capital allocation strategy. Organizations pursue M&A ...

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San Francisco. It's likely no coincidence that Monday has already featured a ...

AI is now central to how companies and investors source, structure and close deals, providing a critical edge in an environment where speed, precision and risk management are paramount. With its ...

The top five bank M&A deals completed in 2024 had an average value to tangible common equity ratio of 184.7%. The average deal value at announcement for these top five bank mergers was $433.5 million.

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular Therapies in the first month of 2025 suggested it would be a big year for high-priced transactions in the biopharma industry. But it was a ...

As 2025 draws to a close, the healthcare mergers and acquisitions (“M&A”) market remains active but increasingly selective. After two years of recalibration following the post-pandemic boom, ...

Artificial intelligence is transforming M&A, allowing for rapid data analysis and strategic insights, outpacing traditional methods. AI automates parts of the acquisition process, from identifying ...

TOKYO/HONG KONG, June 26 (Reuters) - Japan is driving Asia's M&A rebound in 2025 with a record $232 billion worth of deals in the first half, and bankers expect the trend to sustain fuelled by ...

As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug ...